Le Lézard
Classified in: Health
Subjects: PLW, MAT

DNA Hair Regeneration files first patent to regrow hair with human cells


CLEARWATER, Fla., Feb. 20, 2018 /PRNewswire/ -- John Satino, Research coordinator at Hair & Scalp Clinics Clearwater Fl., confirmed their application of a US provisional Patent July 14 2017 to extract growth factors and circulating stem cells from human blood for hair re-growth. This is also combined with consumption of an extract of Aphanizomenon to mobilize CD34+CD133 Stem Cells. The process involves injecting hair roots on balding scalps one at a time, and usually takes three to five hrs., besides blood draw and lab time. Cost is around two thousand dollars. Satino stated they have injected over seventy five individuals to date, with one hundred percent success.  The company has posted the technical information along with several before and after photos on the web site www.DNAhairRegeneration.com.

Media Contact: John Santino, 800-883-4247, [email protected]

SOURCE DNA Hair Regeneration


These press releases may also interest you

at 07:45
Sensi.AI Appoints Renowned Home Care Advocate, Bob Roth, to its Advisory Board Combining Data-Driven Insights with Decades of Home Care Expertise to Revolutionize Aging in Place
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...

at 07:05
Executive War College to Address, Clinical Laboratories' and Genetic Testing Firms' Perfect Storm, involving FDA's Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

More news about Health...


News published on and distributed by: